RoActemra approval expanded to juvenile arthritis in Europe
This article was originally published in Scrip
Executive Summary
Roche's monoclonal antibody product tocilizumab (RoActemra) has received expanded EU approval for use in systemic juvenile idiopathic arthritis (sJIA) following a positive recommendation by the CHMP in May.